# Lawrence Corey

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3438848/lawrence-corey-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

655	63,462 citations	131	228
papers		h-index	g-index
693 ext. papers	73,945 ext. citations	<b>12.7</b> avg, IF	7.5 L-index

#	Paper	IF	Citations
655	High Rate of Asymptomatic Carriage Associated with Variant Strain Omicron. 2022,		17
654	Innovative vaccine approaches-a Keystone Symposia report <i>Annals of the New York Academy of Sciences</i> , <b>2022</b> ,	6.5	1
653	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , <b>2022</b> , 375, 43-50	33.3	116
652	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S <i>New England Journal of Medicine</i> , <b>2022</b> ,	59.2	8
651	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study <i>Lancet, The</i> , <b>2022</b> , 399, 1141-1153	40	7
650	HSV-2-Specific Human Female Reproductive Tract Tissue Resident Memory T Cells Recognize Diverse HSV Antigens <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 867962	8.4	0
649	High Asymptomatic Carriage with the Omicron Variant in South Africa <i>Clinical Infectious Diseases</i> , <b>2022</b> ,	11.6	10
648	Expanding Efforts and Support to Respond to the HIV and COVID-19 Intersecting Pandemics <i>JAMA - Journal of the American Medical Association</i> , <b>2022</b> ,	27.4	1
647	Accelerating clinical trial development in vaccinology: COVID-19 and beyond <i>Current Opinion in Immunology</i> , <b>2022</b> , 76, 102206	7.8	1
646	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2	36
645	Broadly neutralizing monoclonal antibodies for HIV prevention. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24 Suppl 7, e25829	5.4	1
644	Methods to Measure Antibody Neutralization of Live Human Coronavirus OC43. Viruses, 2021, 13,	6.2	1
643	Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 50-60	11.6	8
642	Evaluating the Efficacy of Coronavirus Disease 2019 Vaccines. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 154	40 <u>-11₁5∕</u> 94	1 9
641	Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1089-1100	59.2	36
640	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1003-1014	59.2	77
639	Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2021</b> , 87, 671-679	3.1	6

# (2021-2021)

	The path to find an HIV vaccine. <i>Journal of the International AIDS Society</i> , <b>2021</b> , 24, e25749	5.4	3
637	A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2021</b> , 87, 680-687	3.1	6
636	B cells, antibody-secreting cells, and virus-specific antibodies respond to herpes simplex virus 2 reactivation in skin. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	6
635	A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue. <i>Scientific Reports</i> , <b>2021</b> , 11, 12921	4.9	
634	Distinct populations of antigen-specific tissue-resident CD8+ T cells in human cervix mucosa. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	3
633	Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2187-2201	59.2	865
632	Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. <i>PLoS Computational Biology</i> , <b>2021</b> , 17, e1009072	5	1
631	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 221-228	8	47
630	CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. <i>Journal of Clinical Investigation</i> , <b>2021</b> , 131,	15.9	11
	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, <b>2021</b> ,		
629	384, 403-416	59.2	3691
629 628		59.2 8.8	<ul><li>3691</li><li>7</li></ul>
	384, 403-416  Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of		
628	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , <b>2021</b> , 64, 103203  CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. <i>Molecular</i>	8.8	7
628	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , <b>2021</b> , 64, 103203  CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 20, 258-275  Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated	8.8	7 24
628 627 626	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , <b>2021</b> , 64, 103203  CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 20, 258-275  Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-10	8.8 6.4 4.4	7 24 4
628 627 626	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , <b>2021</b> , 64, 103203  CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 20, 258-275  Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-10  After the pandemic: perspectives on the future trajectory of COVID-19. <i>Nature</i> , <b>2021</b> , 596, 495-504  A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo	8.8 6.4 4.4 50.4	7 24 4 68
628 627 626 625	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , <b>2021</b> , 64, 103203  CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 20, 258-275  Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 1-10  After the pandemic: perspectives on the future trajectory of COVID-19. <i>Nature</i> , <b>2021</b> , 596, 495-504  A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1118-1125	8.8 6.4 4.4 50.4	7 24 4 68 9

620	Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor Titells in rhesus macaques. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2021</b> , 22, 304-319	6.4	1
619	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , <b>2021</b> , 13,	6.2	3
618	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. <i>New England Journal of Medicine</i> , <b>2021</b> ,	59.2	112
617	Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation <b>2021</b> ,		1
616	Tissue-Resident-Memory CD8 T Cells Bridge Innate Immune Responses in Neighboring Epithelial Cells to Control Human Genital Herpes. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 735643	8.4	1
615	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 1774-1785	59.2	105
614	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , <b>2021</b> , eab3435	33.3	84
613	Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study. <i>PLoS Medicine</i> , <b>2021</b> , 18, e1003868	11.6	2
612	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation <i>Scientific Reports</i> , <b>2021</b> , 11, 23921	4.9	10
6-1-1			
611	A strategic approach to COVID-19 vaccine R&D. <i>Science</i> , <b>2020</b> , 368, 948-950	33.3	276
610	A strategic approach to COVID-19 vaccine R&D. <i>Science</i> , <b>2020</b> , 368, 948-950  Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2334-2336	33·3 27·4	276 18
	Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March		
610	Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2334-2336  An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open</i>	27.4	18
610	Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2334-2336  An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa232  Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: Alrandomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438)	27.4	18
610 609 608	Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2334-2336  An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa232  Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: Alrandomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003038  HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime	27.4 1 11.6	18 12 14
610 609 608	Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2334-2336  An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa232  Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: Al'andomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003038  HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , <b>2020</b> , 10, 2093  Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated	27.4 1 11.6 4.9	18 12 14 10
610 609 608 607	Changes in SARS-CoV-2 Positivity Rate in Outpatients in Seattle and Washington State, March 1-April 16, 2020. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 323, 2334-2336  An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa232  Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: Alfandomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003038  HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. <i>Scientific Reports</i> , <b>2020</b> , 10, 2093  Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , <b>2020</b> , 16, e1007626  Brief Report: Prediction of Serum HIV-1 Neutralization Titers After Passive Administration of	27.4 1 11.6 4.9	18 12 14 10 10

#### (2019-2020)

602	Robust antibody and cellular responses induced by DNA-only vaccination for HIV. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	11
601	Tissue-resident T cell-derived cytokines eliminate herpes simplex virus-2-infected cells. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 2903-2919	15.9	23
600	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , <b>2020</b> , 15, e0226803	3.7	10
599	High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results <b>2020</b> ,		17
598	Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials <b>2020</b> ,		13
597	The complex challenges of HIV vaccine development require renewed and expanded global commitment. <i>Lancet, The</i> , <b>2020</b> , 395, 384-388	40	26
596	Prospects for a safe COVID-19 vaccine. Science Translational Medicine, 2020, 12,	17.5	99
595	Use of adenovirus type-5 vectored vaccines: a cautionary tale. <i>Lancet, The</i> , <b>2020</b> , 396, e68-e69	40	31
594	Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e688-e698	7.8	28
593	Real-Time Killing Assays to Assess the Potency of a New Anti-Simian Immunodeficiency Virus Chimeric Antigen Receptor T Cell. <i>AIDS Research and Human Retroviruses</i> , <b>2020</b> , 36, 998-1009	1.6	1
592	Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. <i>Vaccine</i> , <b>2020</b> , 38, 5814-5821	4.1	1
591	The association of All expression with HIV acquisition and disease progression in people who inject drugs and men who have sex with men: Case control studies. <i>EBioMedicine</i> , <b>2020</b> , 62, 103102	8.8	2
590	Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults. <i>Vaccines</i> , <b>2020</b> , 8,	5.3	4
589	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials <b>2020</b> , 16, e1007626		
588	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials <b>2020</b> , 16, e1007626		
587	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials <b>2020</b> , 16, e1007626		
586	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials <b>2020</b> , 16, e1007626		
585	Human Herpesvirus 6B and Lower Respiratory Tract Disease After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2670-2681	2.2	12

584	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , <b>2019</b> , 26, 336-346.e3	23.4	43
583	Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	24
582	Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e737-e749	7.8	23
581	The aspirational necessity of HIV prevention. <i>Journal of the International AIDS Society</i> , <b>2019</b> , 22, e25289	5.4	2
580	Random-Reaction-Seed Method for Automated Identification of Neurite Elongation and Branching. <i>Scientific Reports</i> , <b>2019</b> , 9, 2908	4.9	2
579	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , <b>2019</b> , 129, 4838-4849	15.9	55
578	Antigenic competition in CD4 T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	8
577	Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2741	8.4	14
576	Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	6
575	Nonprimary Maternal Cytomegalovirus Infection After Viral Shedding in Infants. <i>Pediatric Infectious Disease Journal</i> , <b>2018</b> , 37, 627-631	3.4	19
574	Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, S20	4.7	4
573	A Fixed Spatial Structure of CD8 T Cells in Tissue during Chronic HSV-2 Infection. <i>Journal of Immunology</i> , <b>2018</b> , 201, 1522-1535	5.3	13
572	Herpes Simplex Virus Shedding Rate: Surrogate Outcome for Genital Herpes Recurrence Frequency and Lesion Rates, and Phase 2 Clinical Trials End Point for Evaluating Efficacy of Antivirals. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, 1691-1699	7	12
571	Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa. <i>AIDS Research and Human Retroviruses</i> , <b>2018</b> , 34, 645-656	1.6	13
570	Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. <i>Sexually Transmitted Infections</i> , <b>2018</b> , 94, 568-570	2.8	4
569	Increase in HSV shedding at initiation of antiretroviral therapy and decrease in shedding over time on antiretroviral therapy in HIV and HSV-2 infected persons. <i>Aids</i> , <b>2018</b> , 32, 2525-2531	3.5	8
568	Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. <i>Lancet HIV,the</i> , <b>2018</b> , 5, e366-e378	7.8	62
567	Preventing acquisition of HIV is the only path to an AIDS-free generation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, 3798-3800	11.5	12

# (2016-2017)

566	Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. <i>MAbs</i> , <b>2017</b> , 9, 792-800	6.6	33	
565	Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 1376-1385	7	43	
564	Transient Oral Human Cytomegalovirus Infections Indicate Inefficient Viral Spread from Very Few Initially Infected Cells. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	30	
563	Cytomegalovirus (CMV) DNA Quantitation in Bronchoalveolar Lavage Fluid From Hematopoietic Stem Cell Transplant Recipients With CMV Pneumonia. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 215, 1514-1	5⁄22	40	
562	Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract. <i>Mucosal Immunology</i> , <b>2017</b> , 10, 1259-1269	9.2	38	
561	Broadly neutralizing antibodies to prevent HIV-1. <i>Science</i> , <b>2017</b> , 358, 46-47	33.3	10	
560	DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 T-Cell Responses by Interleukin-12 Plasmid DNA. <i>Vaccine Journal</i> , <b>2017</b> , 24,		24	
559	Virus and host-specific differences in oral human herpesvirus shedding kinetics among Ugandan women and children. <i>Scientific Reports</i> , <b>2017</b> , 7, 13105	4.9	11	
558	Adoptive Immunotherapy of Viral Infections: Should Infectious Disease Embrace Cellular Immunotherapy?. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 926-928	7	6	
557	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , <b>2017</b> , 12, e0176428	3.7	11	
556	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , <b>2017</b> , 14, e1002435	11.6	71	
555	Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 1534-1540	7	14	
554	Valganciclovir for the Suppression of Epstein-Barr Virus Replication. <i>Journal of Infectious Diseases</i> , <b>2017</b> , 216, 198-202	7	20	
553	Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. <i>Journal of Experimental Medicine</i> , <b>2017</b> , 214, 2315-2329	16.6	26	
552	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , <b>2017</b> , 9,	0.7	50	
551	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185959	3.7	20	
550	A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. <i>Vaccine</i> , <b>2016</b> , 34, 5792-5801	4.1	12	
549	Dynamics of Persistent Oral Cytomegalovirus Shedding During Primary Infection in Ugandan Infants. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 1735-1743	7	13	

548	No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 258-64	7	13
547	Approaches to preventative and therapeutic HIV vaccines. <i>Current Opinion in Virology</i> , <b>2016</b> , 17, 104-109	97.5	47
546	Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 324ra15	17.5	19
545	Prospective Characterization of the Risk Factors for Transmission and Symptoms of Primary Human Herpesvirus Infections Among Ugandan Infants. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 36-44	7	36
544	Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. <i>Current Opinion in Virology</i> , <b>2016</b> , 17, 57-65	7.5	11
543	Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 213, 1573-8	7	7
542	Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. <i>Clinical Microbiology Reviews</i> , <b>2016</b> , 29, 149-61	34	100
541	Genital Herpes Simplex Virus Type 2 Shedding Among Adults With and Without HIV Infection in Uganda. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 213, 439-47	7	12
540	Mathematical Modeling Predicts that Increased HSV-2 Shedding in HIV-1 Infected Persons Is Due to Poor Immunologic Control in Ganglia and Genital Mucosa. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155124	3.7	14
539	Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. <i>PLoS ONE</i> , <b>2016</b> , 11, e0161753	3.7	11
538	In Situ Staining and Laser Capture Microdissection of Lymph Node Residing SIV Gag-Specific CD8+ T cellsA Tool to Interrogate a Functional Immune Response Ex Vivo. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149907	3.7	3
537	In Situ Detection of Regulatory T Cells in Human Genital Herpes Simplex Virus Type 2 (HSV-2) Reactivation and Their Influence on Spontaneous HSV-2 Reactivation. <i>Journal of Infectious Diseases</i> , <b>2016</b> , 214, 23-31	7	12
536	Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 316, 2495-2503	27.4	44
535	Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults. Sexually Transmitted Diseases, <b>2016</b> , 43, 756-760	2.4	47
534	Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. <i>Vaccine Journal</i> , <b>2016</b> , 23, 496	-506	18
533	HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , <b>2015</b> , 349, aab1253	33.3	144
532	Image analysis for accurately counting CD4+ and CD8+ T cells in human tissue. <i>Journal of Virological Methods</i> , <b>2015</b> , 222, 117-21	2.6	20
531	Plasma cytokine levels and risk of HIV type 1 (HIV-1) transmission and acquisition: a nested case-control study among HIV-1-serodiscordant couples. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 1451-	- <i>6</i> 0	39

530	Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials. <i>Vaccine</i> , <b>2015</b> , 33, 2347-53	4.1	29
529	Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 31-	.9 <sup>11.6</sup>	84
528	Clinical outcomes associated with respiratory virus detection before allogeneic hematopoietic stem cell transplant. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 192-202	11.6	90
527	A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. <i>Journal of Virology</i> , <b>2015</b> ,	6.6	17
526	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 310rv7	17.5	142
525	HIV-1 infections with multiple founders are associated with higher viral loads than infections with single founders. <i>Nature Medicine</i> , <b>2015</b> , 21, 1139-41	50.5	29
524	Plasma and cerebrospinal fluid herpes simplex virus levels at diagnosis and outcome of neonatal infection. <i>Journal of Pediatrics</i> , <b>2015</b> , 166, 827-33	3.6	33
523	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136626	3.7	15
522	Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models. <i>EBioMedicine</i> , <b>2015</b> , 2, 2062-9	8.8	10
521	Use of placebos in Phase 1 preventive HIV vaccine clinical trials. <i>Vaccine</i> , <b>2015</b> , 33, 749-52	4.1	1
520	Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137666	3.7	22
519	Herpes Simplex Virus <b>2015</b> , 1713-1730.e6		3
518	Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. <i>Lancet Infectious Diseases, The</i> , <b>2014</b> , 14, 388-96	25.5	80
517	Summary and recommendations from a National Institute of Allergy and Infectious Diseases (NIAID) workshop on "Next Generation Herpes Simplex Virus Vaccines". <i>Vaccine</i> , <b>2014</b> , 32, 1561-2	4.1	16
516	Helicase-primase inhibitor pritelivir for HSV-2 infection. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 201-10	59.2	95
515	Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection. <i>Journal of Virology</i> , <b>2014</b> , 88, 4921-31	6.6	46
514	Frequent genital HSV-2 shedding among women during labor in Soweto, South Africa. <i>Infectious Diseases in Obstetrics and Gynecology</i> , <b>2014</b> , 2014, 258291	2.4	15
513	Nuclear factor kappa B is required for the production of infectious human herpesvirus 8 virions. <i>Frontiers in Microbiology</i> , <b>2014</b> , 5, 129	5.7	6

512	HVTN 097: Evaluation of the RV144 Vaccine Regimen in HIV Uninfected South African Adults. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, A33-A34	1.6	17
511	Phase I/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime/LIPO-5 boost in healthy, HIV-1-uninfected adult participants. <i>Vaccine Journal</i> , <b>2014</b> , 21, 1589-99		8
510	Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. <i>Journal of Clinical Virology</i> , <b>2014</b> , 60, 127-32	14.5	22
509	Mortality rates of human metapneumovirus and respiratory syncytial virus lower respiratory tract infections in hematopoietic cell transplantation recipients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 1220-6	4.7	101
508	Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. New England Journal of Medicine, 2013, 369, 2083	3- <del>9</del> 3.2	434
507	The need and challenges for development of an Epstein-Barr virus vaccine. <i>Vaccine</i> , <b>2013</b> , 31 Suppl 2, B194-6	4.1	62
506	Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. <i>Nature Medicine</i> , <b>2013</b> , 19, 280-90	50.5	73
505	Immune surveillance by CD8⊞ skin-resident T cells in human herpes virus infection. <i>Nature</i> , <b>2013</b> , 497, 494-7	50.4	209
504	High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 63, 201-8	3.1	15
503	HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. <i>PLoS Pathogens</i> , <b>2013</b> , 9, e1003404	7.6	30
502	Reply to Richie and Villasante. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 207, 690-2	7	1
501	Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial. <i>Journal of Infectious Diseases</i> , <b>2013</b> , 208, 1366-74	7	35
500	Self-collection of foam nasal swabs for respiratory virus detection by PCR among immunocompetent subjects and hematopoietic cell transplant recipients. <i>Journal of Clinical Microbiology</i> , <b>2013</b> , 51, 324-7	9.7	24
499	Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 5820	<b>-5</b> -9	30
498	HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 13492-7	11.5	35
497	Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract. <i>ELife</i> , <b>2013</b> , 2, e00288	8.9	50
496	Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy. <i>PLoS ONE</i> , <b>2013</b> , 8, e65071	3.7	12
495	Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. <i>Lancet, The</i> , <b>2012</b> , 379, 641-7	40	90

494	HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 1700-8	4.7	95
493	Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biology of Blood and Marrow Transplantation, <b>2012</b> , 18, 1391-1400	4.7	45
492	An effector phenotype of CD8+ T cells at the junction epithelium during clinical quiescence of herpes simplex virus 2 infection. <i>Journal of Virology</i> , <b>2012</b> , 86, 10587-96	6.6	41
491	Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2012</b> , 18, 1687-99	4.7	119
490	Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. <i>PLoS ONE</i> , <b>2012</b> , 7, e33969	3.7	21
489	MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load. <i>PLoS ONE</i> , <b>2012</b> , 7, e43396	3.7	27
488	WU and KI polyomaviruses in respiratory samples from allogeneic hematopoietic cell transplant recipients. <i>Emerging Infectious Diseases</i> , <b>2012</b> , 18, 1580-8	10.2	31
487	A prospective cohort study of partner testing for herpes simplex virus and sexual behavior during pregnancy. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 486-94	7	9
486	Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 258-66	7	161
485	Influenza viral RNA detection in blood as a marker to predict disease severity in hematopoietic cell transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2012</b> , 206, 1872-7	7	32
484	HIV Vaccine Trials Network: activities and achievements of the first decade and beyond. <i>Clinical Investigation</i> , <b>2012</b> , 2, 245-254		8
483	Acyclovir achieves a lower concentration in African HIV-seronegative, herpes simplex virus 2-seropositive women than in non-African populations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 2777-9	5.9	16
482	Human immunodeficiency virus vaccine trials. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007	35.4	43
481	Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. <i>Sexually Transmitted Diseases</i> , <b>2012</b> , 39, 21-4	2.4	4
480	Changes in the soluble mucosal immune environment during genital herpes outbreaks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2012</b> , 61, 194-202	3.1	22
479	Xenotropic murine leukemia virus-related virus in monozygotic twins discordant for chronic fatigue syndrome. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2011</b> , 71, 66-71	2.9	5
47 <sup>8</sup>	Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 979-86	4.7	49
477	Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. <i>Journal of Clinical Virology</i> , <b>2011</b> , 50, 4-7	14.5	6

476	Introduction of a novel parechovirus RT-PCR clinical test in a regional medical center. <i>Journal of Clinical Virology</i> , <b>2011</b> , 51, 50-3	14.5	29
475	A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. <i>Vaccine</i> , <b>2011</b> , 29, 1948-58	4.1	47
474	Development of an interferon-gamma ELISPOT assay to detect human T cell responses to HSV-2. <i>Vaccine</i> , <b>2011</b> , 29, 7058-66	4.1	10
473	Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. <i>Lancet Infectious Diseases, The</i> , <b>2011</b> , 11, 507-15	25.5	272
472	Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. <i>PLoS ONE</i> , <b>2011</b> , 6, e16986	3.7	72
471	Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. <i>PLoS ONE</i> , <b>2011</b> , 6, e20479	3.7	53
470	A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). <i>PLoS ONE</i> , <b>2011</b> , 6, e21225	3.7	120
469	Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study. <i>Aids</i> , <b>2011</b> , 25, 153-8	3.5	23
468	HHV-6 reactivation and its effect on delirium and cognitive functioning in hematopoietic cell transplantation recipients. <i>Blood</i> , <b>2011</b> , 117, 5243-9	2.2	105
467	Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. <i>Blood</i> , <b>2011</b> , 117, 5050-6	2.2	114
466	HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. <i>Blood</i> , <b>2011</b> , 117, 5391-402	2.2	38
465	Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. <i>Haematologica</i> , <b>2011</b> , 96, 1838-45	6.6	37
464	Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. <i>Nature Medicine</i> , <b>2011</b> , 17, 366-71	50.5	186
463	A siege of hepatitis: fighting a defiant virus. <i>Nature Medicine</i> , <b>2011</b> , 17, 253-4	50.5	4
462	Treatment with valacyclovir, famciclovir, or antiretrovirals reduces human herpesvirus-8 replication in HIV-1 seropositive men. <i>Journal of Medical Virology</i> , <b>2011</b> , 83, 1696-703	19.7	18
461	H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. <i>Emerging Infectious Diseases</i> , <b>2011</b> , 17, 653-60; quiz 765	10.2	44
460	HIV-1 vaccines and adaptive trial designs. Science Translational Medicine, 2011, 3, 79ps13	17.5	54
459	Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 2593-600	5.1	29

# (2010-2011)

458	Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 1474-83	7	247
457	The HIV protease inhibitor nelfinavir inhibits KaposiN sarcoma-associated herpesvirus replication in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2011</b> , 55, 2696-703	5.9	58
456	Genital HSV detection among HIV-1-infected pregnant women in labor. <i>Infectious Diseases in Obstetrics and Gynecology</i> , <b>2011</b> , 2011, 157680	2.4	13
455	Detection of adeno-associated virus viremia in hematopoietic cell transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 1746-9	7	5
454	A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. <i>Statistical Communications in Infectious Diseases</i> , <b>2011</b> , 3,	0.7	19
453	Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 1441-9	27.4	196
452	Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 57, 238-44	3.1	55
451	Clinician and patient recognition of anogenital herpes disease in HIV positive men who have sex with men. <i>Sexually Transmitted Diseases</i> , <b>2011</b> , 38, 833-6	2.4	2
450	Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. <i>Science Translational Medicine</i> , <b>2011</b> , 3, 77ra29	17.5	233
449	Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 117-21	7	17
448	The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 204, 554-61	7	45
447	Persistent genital herpes simplex virus-2 shedding years following the first clinical episode. <i>Journal of Infectious Diseases</i> , <b>2011</b> , 203, 180-7	7	55
446	Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. <i>PLoS ONE</i> , <b>2011</b> , 6, e25571	3.7	32
445	HIV vaccines: mosaic approach to virus diversity. <i>Nature Medicine</i> , <b>2010</b> , 16, 268-70	50.5	22
444	Frequent detection of human adenovirus from the lower gastrointestinal tract in men who have sex with men. <i>PLoS ONE</i> , <b>2010</b> , 5, e11321	3.7	10
443	Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. <i>PLoS ONE</i> , <b>2010</b> , 5, e12598	3.7	110
442	Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: Detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. <i>Annals of Internal Medicine</i> , <b>2010</b> , 152, 619-20	8	21
441	Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. <i>Journal of Immunology</i> , <b>2010</b> , 184, 3250-9	5.3	53

440	Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 1579-86	12.7	83
439	Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 1404-13	7	77
438	Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 499-504	7	24
437	Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 18973-8	11.5	93
436	Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. <i>Journal of Infectious Diseases</i> , <b>2010</b> , 201, 1164-8	7	22
435	Rapid polymerase chain reaction assay to detect herpes simplex virus in the genital tract of women in labor. <i>Obstetrics and Gynecology</i> , <b>2010</b> , 115, 1209-1216	4.9	25
434	Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. <i>Lancet, The,</i> <b>2010</b> , 375, 824-33	40	128
433	Rapidly cleared episodes of oral and anogenital herpes simplex virus shedding in HIV-infected adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2010</b> , 54, 482-8	3.1	36
432	Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. <i>Blood</i> , <b>2010</b> , 115, 2088-94	2.2	142
431	Diversity in CD8(+) T cell function and epitope breadth among persons with genital herpes. <i>Journal of Clinical Immunology</i> , <b>2010</b> , 30, 703-22	5.7	44
430	In situ detection of Gag-specific CD8+ cells in the GI tract of SIV infected Rhesus macaques. <i>Retrovirology</i> , <b>2010</b> , 7, 12	3.6	23
429	Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. <i>Pediatric Blood and Cancer</i> , <b>2010</b> , 54, 670-4	3	51
428	Gender differences in clinical presentation and outcomes of epidemic Kaposi sarcoma in Uganda. <i>PLoS ONE</i> , <b>2010</b> , 5, e13936	3.7	34
427	Herpes Simplex Virus <b>2010</b> , 1943-1962		5
426	Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. <i>Sexually Transmitted Diseases</i> , <b>2010</b> , 37, 290-7	2.4	30
425	Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. <i>PLoS ONE</i> , <b>2009</b> , 4, e5272	3.7	66
424	Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation. <i>Haematologica</i> , <b>2009</b> , 94, 1101-8	6.6	79
423	Vaccine prevention of maternal cytomegalovirus infection. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 1191-9	59.2	523

#### (2009-2009)

422	Hepatitis C virus is infrequently evaluated and treated in an urban HIV clinic population. <i>AIDS Patient Care and STDs</i> , <b>2009</b> , 23, 925-9	5.8	26
421	Evasion of the mucosal innate immune system by herpes simplex virus type 2. <i>Journal of Virology</i> , <b>2009</b> , 83, 12559-68	6.6	47
420	The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, e120-3	11.6	3
419	Clinical correlates of herpes simplex virus viremia among hospitalized adults. <i>Clinical Infectious Diseases</i> , <b>2009</b> , 49, 1295-301	11.6	62
418	The acceptance of HSV-testing partners of HSV-2 seronegative pregnant women. <i>Sexually Transmitted Diseases</i> , <b>2009</b> , 36, 211-5	2.4	5
417	CDC recommendations for opt-out HIV testing. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 274-5; author reply 275-6	27.4	3
416	Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners. <i>Journal of Virology</i> , <b>2009</b> , 83, 10821-9	6.6	10
415	Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. <i>Science Translational Medicine</i> , <b>2009</b> , 1, 7ra16	17.5	82
414	New concepts in understanding genital herpes. Current Infectious Disease Reports, 2009, 11, 457-64	3.9	43
413	Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. <i>Nature Medicine</i> , <b>2009</b> , 15, 886-92	50.5	298
412	Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 694-703	4.7	63
411	Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. <i>Vaccine</i> , <b>2009</b> , 27, 243-9	4.1	46
410	Gram-negative bloodstream infections in hematopoietic stem cell transplant patients: the roles of needleless device use, bathing practices, and catheter care. <i>American Journal of Infection Control</i> , <b>2009</b> , 37, 327-34	3.8	16
409	Maternal and neonatal herpes simplex virus infections. New England Journal of Medicine, 2009, 361, 13	7 <del>6</del> - <u>8,5</u>	289
408	HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men. <i>Aids</i> , <b>2009</b> , 23, 479-83	3.5	40
407	Uptake of male circumcision in an HIV vaccine efficacy trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2009</b> , 51, 108-10	3.1	12
406	Inadequacy of plasma acyclovir levels at delivery in patients with genital herpes receiving oral acyclovir suppressive therapy in late pregnancy. <i>Journal of Obstetrics and Gynaecology Canada</i> , <b>2009</b> , 31, 1137-43	1.3	4
405	Impact of HIV infection and Kaposi sarcoma on human herpesvirus-8 mucosal replication and dissemination in Uganda. <i>PLoS ONE</i> , <b>2009</b> , 4, e4222	3.7	42

404	Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. <i>PLoS ONE</i> , <b>2009</b> , 4, e6949	3.7	27
403	Env length and N-linked glycosylation following transmission of human immunodeficiency virus Type 1 subtype B viruses. <i>Virology</i> , <b>2008</b> , 374, 229-33	3.6	67
402	Herpes simplex: insights on pathogenesis and possible vaccines. <i>Annual Review of Medicine</i> , <b>2008</b> , 59, 381-95	17.4	172
401	Development of multiplexed real-time quantitative polymerase chain reaction assay for detecting human adenoviruses. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2008</b> , 62, 263-71	2.9	26
400	Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2008</b> , 371, 2109-1	9 <sup>40</sup>	363
399	Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. <i>Lancet, The</i> , <b>2008</b> , 372, 1881-1893	40	1343
398	HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. <i>Lancet, The,</i> <b>2008</b> , 372, 1894-1905	40	600
397	Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. <i>Vaccine Journal</i> , <b>2008</b> , 15, 1638-43		62
396	Towards prediction of degenerate CTL epitope recognition. <i>Hum Vaccin</i> , <b>2008</b> , 4, 115-21		6
395	Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). <i>AIDS Research and Human Retroviruses</i> , <b>2008</b> , 24, 561-71	1.6	47
394	Blood monocytes harbor HIV type 1 strains with diversified phenotypes including macrophage-specific CCR5 virus. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 197, 309-18	7	31
393	Gamma delta+ T cells involvement in viral immune control of chronic human herpesvirus 8 infection. <i>Journal of Immunology</i> , <b>2008</b> , 180, 3417-25	5.3	29
392	The use of nonhuman primate models in HIV vaccine development. PLoS Medicine, 2008, 5, e173	11.6	83
391	Herpes simplex virus viremia during primary genital infection. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 31-4	7	60
390	Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 1804-8	7	122
389	Cytomegalovirus reactivation in critically ill immunocompetent patients. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 413-22	27.4	300
388	Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 1141-9	7	207
387	Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. <i>Journal of Infectious Diseases</i> , <b>2008</b> , 198, 23-30	7	122

#### (2007-2008)

386	Independent and cooperative antiviral actions of beta interferon and gamma interferon against herpes simplex virus replication in primary human fibroblasts. <i>Journal of Virology</i> , <b>2008</b> , 82, 1934-45	6.6	30
385	Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study. <i>Sexually Transmitted Diseases</i> , <b>2008</b> , 35, 124-8	2.4	10
384	Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. <i>PLoS ONE</i> , <b>2008</b> , 3, e2230	3.7	188
383	Expression of concern. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 1974	15.9	3
382	Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. <i>Acta Obstetricia Et Gynecologica Scandinavica</i> , <b>2007</b> , 86, 523-9	3.8	34
381	Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 1762-4	7	154
380	Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. <i>Journal of Clinical Microbiology</i> , <b>2007</b> , 45, 2681-3	9.7	31
379	HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. <i>Current HIV Research</i> , <b>2007</b> , 5, 97-107	1.3	24
378	Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 1500-8	7	166
377	Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2007</b> , 44, 203-12	3.1	92
376	Synergistic copathogensHIV-1 and HSV-2. New England Journal of Medicine, 2007, 356, 854-6	59.2	90
375	Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 187-93	11.6	73
374	Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. <i>Sexually Transmitted Infections</i> , <b>2007</b> , 83, 359-64	2.8	36
373	Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. <i>Journal of Experimental Medicine</i> , <b>2007</b> , 204, 595-603	16.6	272
372	Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 1242-4	7	31
371	Frequent and asymptomatic oropharyngeal shedding of human herpesvirus 8 among immunocompetent men. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 30-6	7	79
370	Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 958-65	11.6	72
369	Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 266-70	7	93

368	Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 1324-31	7	88
367	A framework for assessing immunological correlates of protection in vaccine trials. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 196, 1304-12	7	161
366	Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. <i>Blood</i> , <b>2007</b> , 110, 1681-8	2.2	183
365	One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. <i>Blood</i> , <b>2007</b> , 110, 3071-7	2.2	168
364	HIV vaccine effectiveness and the mucosal interface. Future HIV Therapy, 2007, 1, 127-129		
363	Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients. <i>Transplantation</i> , <b>2007</b> , 83, 1423-8	1.8	36
362	Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. <i>Obstetrics and Gynecology</i> , <b>2007</b> , 109, 403-9	4.9	49
361	Antimicrobial resistance prevention initiativean update: proceedings of an expert panel on resistance. <i>American Journal of Infection Control</i> , <b>2007</b> , 35, S1-23; quiz S24-6	3.8	30
360	Antimicrobial resistance prevention initiativean update: proceedings of an expert panel on resistance. <i>American Journal of Medicine</i> , <b>2007</b> , 120, S4-25; quiz S26-8	2.4	33
359	Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. <i>American Journal of Pathology</i> , <b>2007</b> , 170, 478-89	5.8	81
358	A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients <i>Blood</i> , <b>2007</b> , 110, 2975-2975	2.2	
357	Polymerase chain reaction diagnosis of primary human herpesvirus-6 infection in the acute care setting. <i>Journal of Pediatrics</i> , <b>2006</b> , 149, 480-5	3.6	8
356	Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 194, 420-7	7	42
355	Sequence-based methods for identifying epidemiologically linked herpes simplex virus type 2 strains. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 2541-6	9.7	15
354	HIV vaccines: new frontiers in vaccine development. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43, 500-11	11.6	96
353	Continued evolution of HIV-1 circulating in blood monocytes with antiretroviral therapy: genetic analysis of HIV-1 in monocytes and CD4+ T cells of patients with discontinued therapy. <i>Journal of Leukocyte Biology</i> , <b>2006</b> , 80, 1118-26	6.5	29
352	High serum hepatitis C virus (HCV) RNA load predicts the presence of HCV RNA in saliva from individuals with chronic and acute HCV infection. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 672-6	7	21
351	Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. <i>Journal of Virology</i> , <b>2006</b> , 80, 5509-15	6.6	91

# (2005-2006)

350	Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 1619-25	7	142
349	Selection on the human immunodeficiency virus type 1 proteome following primary infection. <i>Journal of Virology</i> , <b>2006</b> , 80, 9519-29	6.6	105
348	Repeat-region polymorphisms in the gene for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: effects on HIV-1 susceptibility. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 698-702	7	43
347	Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. <i>Journal of Clinical Microbiology</i> , <b>2006</b> , 44, 2382-8	9.7	240
346	CD4+ T cell receptor repertoire perturbations in HIV-1 infection: association with plasma viremia and disease progression. <i>Clinical Immunology</i> , <b>2006</b> , 119, 95-102	9	9
345	Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert. <i>Vaccine</i> , <b>2006</b> , 24, 532-9	4.1	3
344	A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. <i>Vaccine</i> , <b>2006</b> , 24, 914-20	4.1	65
343	Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. <i>Vaccine</i> , <b>2006</b> , 24, 6893-904	4.1	86
342	Genital Herpes Complicating Pregnancy. Obstetrics and Gynecology, 2006, 107, 426	4.9	
341	Human herpesvirus 8 infection among adolescents in the REACH cohort. <i>JAMA Pediatrics</i> , <b>2006</b> , 160, 937-42		13
340	Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. <i>Sexually Transmitted Diseases</i> , <b>2006</b> , 33, 529-33	2.4	60
339	Genital Herpes Complicating Pregnancy. Obstetrics and Gynecology, 2006, 107, 741	4.9	
338	Abacavir hypersensitivity reaction in primary HIV infection. <i>Aids</i> , <b>2006</b> , 20, 1269-74	3.5	33
337	Isolation of herpes simplex virus from the genital tract during symptomatic recurrence on the buttocks. <i>Obstetrics and Gynecology</i> , <b>2006</b> , 108, 947-52	4.9	4
336	Lower genitourinary tract sources of seminal HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), <b>2006</b> , 41, 430-8	3.1	44
335	Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients.  Annals of Internal Medicine, 2006, 144, 344-9	8	194
334	Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. <i>American Journal of Obstetrics and Gynecology</i> , <b>2006</b> , 195, 115-20	6.4	19
333	Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 1102-7	7	29

332	Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. <i>Clinical Infectious Diseases</i> , <b>2005</b> , 40, 932-40	11.6	269
331	Detection and quantification of human metapneumovirus in pediatric specimens by real-time RT-PCR. <i>Journal of Clinical Virology</i> , <b>2005</b> , 33, 299-305	14.5	95
330	Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2005</b> , 11, 136-48	4.7	32
329	Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2005</b> , 11, 521-9	4.7	57
328	Genital herpes complicating pregnancy. Obstetrics and Gynecology, 2005, 106, 845-56	4.9	141
327	Poor correlation between genital lesions and detection of herpes simplex virus in women in labor. <i>Obstetrics and Gynecology</i> , <b>2005</b> , 106, 268-74	4.9	20
326	Neonatal herpes should be a reportable disease. Sexually Transmitted Diseases, 2005, 32, 521-5	2.4	30
325	The relationship between condom use and herpes simplex virus acquisition. <i>Annals of Internal Medicine</i> , <b>2005</b> , 143, 707-13	8	117
324	BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients. <i>Blood</i> , <b>2005</b> , 106, 1130-2	2.2	144
323	Improved outcome in central nervous system aspergillosis, using voriconazole treatment. <i>Blood</i> , <b>2005</b> , 106, 2641-5	2.2	307
322	Risk factors for herpes simplex virus transmission to pregnant women: a couples study. <i>American Journal of Obstetrics and Gynecology</i> , <b>2005</b> , 193, 1891-9	6.4	45
321	Most DC-SIGNR transcripts at mucosal HIV transmission sites are alternatively spliced isoforms. <i>European Journal of Human Genetics</i> , <b>2005</b> , 13, 707-15	5.3	24
320	Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay. <i>Journal of Medical Virology</i> , <b>2005</b> , 76, 350-5	19.7	87
319	Use of "biokit HSV-2 Rapid Assay" to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA. <i>BMC Infectious Diseases</i> , <b>2005</b> , 5, 84	4	55
318	Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice. <i>PLoS Pathogens</i> , <b>2005</b> , 1, e7	7.6	28
317	High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 192, 1249-59	7	60
316	Longitudinal analysis of herpes simplex virus-specific CD4+ cell clonotypes in infected tissues and blood. <i>Journal of Infectious Diseases</i> , <b>2005</b> , 191, 2012-21	7	14
315	Calibration curves for real-time PCR. <i>Clinical Chemistry</i> , <b>2005</b> , 51, 1132-6	5.5	16

#### (2004-2005)

314	How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?. <i>Journal of Virology</i> , <b>2005</b> , 79, 13579-86	6.6	34
313	A population-based study of primary human herpesvirus 6 infection. <i>New England Journal of Medicine</i> , <b>2005</b> , 352, 768-76	59.2	341
312	Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: a randomized clinical trial. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 1466-71	7	50
311	Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 189, 2016-22	7	34
310	CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. <i>Journal of Experimental Medicine</i> , <b>2004</b> , 200, 1407-17	16.6	103
309	Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 693-6	7	92
308	Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. Journal of Infectious Diseases, <b>2004</b> , 190, 1374-81	7	133
307	Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 1300-6	11.6	309
306	Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 1055-8	7	102
305	Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. <i>Journal of Clinical Microbiology</i> , <b>2004</b> , 42, 4130-6	9.7	42
304	Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 673-80	11.6	52
303	HIV infection and human herpesvirus-8 oral shedding among men who have sex with men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2004</b> , 35, 233-8	3.1	50
302	Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. <i>Journal of Virology</i> , <b>2004</b> , 78, 7883-93	6.6	66
301	Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Diseases, 2004, 39, 797-802	11.6	494
300	Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. <i>Journal of Infectious Diseases</i> , <b>2004</b> , 190, 1962-9	7	47
299	BK virus infection in hematopoietic stem cell transplant recipients: frequency, risk factors, and association with postengraftment hemorrhagic cystitis. <i>Clinical Infectious Diseases</i> , <b>2004</b> , 39, 1861-5	11.6	100
298	Persistence of low levels of simian immunodeficiency virus in macaques that were transiently viremic by conventional testing. <i>Virology</i> , <b>2004</b> , 323, 208-19	3.6	12
297	Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. <i>Blood</i> , <b>2004</b> , 103, 1527-33	2.2	371

296	Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. <i>Journal of Clinical Microbiology</i> , <b>2004</b> , 42, 1142-8	9.7	220
295	Once-daily valacyclovir to reduce the risk of transmission of genital herpes. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 11-20	59.2	544
294	Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2004</b> , 10, 58-64	4.7	59
293	Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center. <i>Biology of Blood and Marrow Transplantation</i> , <b>2004</b> , 10, 494-50	34.7	112
292	Safety profile of recombinant canarypox HIV vaccines. <i>Vaccine</i> , <b>2004</b> , 22, 704-13	4.1	51
291	Dual HIV-1 infection associated with rapid disease progression. <i>Lancet, The</i> , <b>2004</b> , 363, 619-22	40	163
<b>2</b> 90	The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2004</b> , 35, 435-45	3.1	442
289	Cyclophosphamide metabolism is affected by azole antifungals. <i>Blood</i> , <b>2004</b> , 103, 1557-9	2.2	163
288	Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. <i>Blood</i> , <b>2004</b> , 103, 1632-4	2.2	169
287	Fatal Human Metapneumovirus Infection in Stem Cell Transplant Recipients <i>Blood</i> , <b>2004</b> , 104, 189-189	2.2	4
286	Prevention of herpes simplex virus type 2 transmission with antiviral therapy. <i>Herpes: the Journal of the IHMF</i> , <b>2004</b> , 11 Suppl 3, 170A-174A		9
285	T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?. <i>Journal of Immunology</i> , <b>2003</b> , 170, 4380-8	5.3	53
284	Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. <i>Journal of Virology</i> , <b>2003</b> , 77, 6867-78	6.6	141
283	How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis?. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 1509-12	7	45
282	Viral hepatitis among young men who have sex with men: prevalence of infection, risk behaviors, and vaccination. <i>Sexually Transmitted Diseases</i> , <b>2003</b> , 30, 425-32	2.4	47
281	Natural history of genital herpes simplex virus type 1 infection. <i>Sexually Transmitted Diseases</i> , <b>2003</b> , 30, 174-7	2.4	114
<b>2</b> 80	Correlates of human herpesvirus-8 seropositivity among U.S. military members recently infected with human immunodeficiency virus. <i>Sexually Transmitted Diseases</i> , <b>2003</b> , 30, 713-8	2.4	9
279	Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. <i>Blood</i> , <b>2003</b> , 101, 4195-200	2.2	180

#### (2003-2003)

278	Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. <i>Blood</i> , <b>2003</b> , 102, 306	50-7	194
277	Herpes simplex virus-associated sepsis in a previously infected immunocompetent adult. <i>Annals of Internal Medicine</i> , <b>2003</b> , 139, 153-4	8	10
276	A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. <i>American Journal of Obstetrics and Gynecology</i> , <b>2003</b> , 188, 836-43	6.4	131
275	Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , <b>2003</b> , 123, 662-	<b>76</b> ·5	28
274	Dynamics of hepatitis C virus replication in human liver. <i>American Journal of Pathology</i> , <b>2003</b> , 163, 433-4	<b>14</b> 5.8	52
273	Provision of treatment in HIV-1 vaccine trials in developing countries. <i>Lancet, The</i> , <b>2003</b> , 362, 993-4	4º	27
272	Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. <i>Biology of Blood and Marrow Transplantation</i> , <b>2003</b> , 9, 341-52	4.7	128
271	Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. <i>Blood</i> , <b>2003</b> , 101, 407-14	2.2	486
270	Evaluation of real-time PCR versus PCR with liquid-phase hybridization for detection of enterovirus RNA in cerebrospinal fluid. <i>Journal of Clinical Microbiology</i> , <b>2003</b> , 41, 3133-41	9.7	42
269	Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 1038-45	7	140
268	Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 12899-904	11.5	51
267	Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 1345-51	7	252
266	Human herpesvirus 8: seroprevalence and correlates in prostitutes in Mombasa, Kenya. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 187, 359-63	7	52
265	What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. <i>Journal of Infectious Diseases</i> , <b>2003</b> , 188, 179-93	7	54
264	Recent progress in herpes simplex virus immunobiology and vaccine research. <i>Clinical Microbiology Reviews</i> , <b>2003</b> , 16, 96-113	34	213
263	Medicine. The need for a global HIV vaccine enterprise. <i>Science</i> , <b>2003</b> , 300, 2036-9	33.3	158
262	Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 36, 1139-43	11.6	112
261	Detection of hepatitis C virus RNA in normal cervical smears. <i>Clinical Infectious Diseases</i> , <b>2003</b> , 37, 314; author reply 314-5	11.6	O

260	Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 289, 203-9	27.4	466
259	Persistence of extraordinarily low levels of genetically homogeneous human immunodeficiency virus type 1 in exposed seronegative individuals. <i>Journal of Virology</i> , <b>2003</b> , 77, 6108-16	6.6	79
258	Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , <b>2003</b> , 77, 2663-74	6.6	35
257	Case report: primary human herpesvirus-6 associated with an afebrile seizure in a 3-week-old infant. <i>Journal of Medical Virology</i> , <b>2002</b> , 66, 384-7	19.7	26
256	Do scarce targets or T killers control primary HIV infection?. <i>Journal of Theoretical Biology</i> , <b>2002</b> , 214, 209-14	2.3	13
255	HHV-8 infection: a model for reactivation and transmission. <i>Reviews in Medical Virology</i> , <b>2002</b> , 12, 47-63	11.7	36
254	Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 909-17	11.6	1163
253	Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 309-17	11.6	182
252	Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. <i>Journal of Virology</i> , <b>2002</b> , 76, 707-16	6.6	262
251	A prospective study of hormonal contraceptive use and cervical shedding of herpes simplex virus in human immunodeficiency virus type 1-seropositive women. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 1822-5	7	34
250	Virus population homogenization following acute human immunodeficiency virus type 1 infection. <i>Journal of Virology</i> , <b>2002</b> , 76, 11953-9	6.6	86
249	Correlates of prevalent and incident KaposiN sarcoma-associated herpesvirus infection in men who have sex with men. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 990-3	7	65
248	Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 34, 944-8	11.6	87
247	Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 29, 254-61	3.1	47
246	Association between cervical shedding of herpes simplex virus and HIV-1. <i>Aids</i> , <b>2002</b> , 16, 2425-30	3.5	107
245	Challenges in genital herpes simplex virus management. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186 Suppl 1, S29-33	7	35
244	High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 273-82	7	330
243	Quantitative stability of DNA after extended storage of clinical specimens as determined by real-time PCR. <i>Journal of Clinical Microbiology</i> , <b>2002</b> , 40, 2609-11	9.7	114

# (2001-2002)

242	Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. <i>Journal of Virology</i> , <b>2002</b> , 76, 10674-84	6.6	64
241	Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. <i>Clinical Infectious Diseases</i> , <b>2002</b> , 35, 518-25	11.6	51
240	Search for polymorphisms in the genes for herpesvirus entry mediator, nectin-1, and nectin-2 in immune seronegative individuals. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 185, 36-44	7	14
239	Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186, 1718-25	7	170
238	Genital shedding of herpes simplex virus among men. <i>Journal of Infectious Diseases</i> , <b>2002</b> , 186 Suppl 1, S34-9	7	61
237	Assessment of a combined testing strategy for detection of antibodies to human herpesvirus 8 (HHV-8) in persons with KaposiN sarcoma, persons with asymptomatic HHV-8 infection, and persons at low risk for HHV-8 infection. <i>Journal of Clinical Microbiology</i> , <b>2002</b> , 40, 3822-5	9.7	25
236	Safety and Immunogenicity of a High-Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV-1 Ininfected Adults: AIDS Vaccine Evaluation Group Protocol 022A. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 29, 254-261	3.1	77
235	Concordance between HIV source partner identification and molecular confirmation in acute retroviral syndrome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 29, 232-43	3.1	14
234	Human herpesvirus 6 infection in febrile infants ninety days of age and younger. <i>Pediatric Infectious Disease Journal</i> , <b>2002</b> , 21, 996-9	3.4	23
233	Potential benefits of a serodiagnostic test for herpes simplex virus type 1 (HSV-1) to prevent neonatal HSV-1 infection. <i>Sexually Transmitted Diseases</i> , <b>2002</b> , 29, 399-405	2.4	6
232	Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. <i>Blood</i> , <b>2002</b> , 99, 1978-85	2.2	197
231	A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. <i>Blood</i> , <b>2002</b> , 99, 2712-9	2.2	143
230	Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. <i>Blood</i> , <b>2002</b> , 100, 4358-66	2.2	806
229	Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2002</b> , 8, 281-9	4.7	72
228	Expression of cutaneous lymphocyte-associated antigen by CD8+ T cells specific for a skin-tropic virus. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 537-548	15.9	97
227	Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 537-48	15.9	58
226	Chlamydia pneumoniae respiratory infection after allogeneic stem cell transplantation. <i>Transplantation</i> , <b>2002</b> , 73, 1002-5	1.8	6
225	Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. <i>Blood</i> , <b>2001</b> , 98, 573-8	2.2	243

224	Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 1343-52	7	128
223	Herpes simplex inhibits the capacity of lymphoblastoid B cell lines to stimulate CD4+ T cells. <i>Journal of Immunology</i> , <b>2001</b> , 166, 6242-9	5.3	41
222	Herpes simplex virus shedding and plasma human immunodeficiency virus RNA levels in coinfected women. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 33, 885-90	11.6	20
221	Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 377-82	7	87
220	Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 350-4	7	149
219	Seroepidemiology of human herpesvirus 8 among young men who have sex with men. <i>Sexually Transmitted Diseases</i> , <b>2001</b> , 28, 176-83	2.4	25
218	Quantitation of BK virus load in serum for the diagnosis of BK virus-associated nephropathy in renal transplant recipients. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 1669-72	7	169
217	CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. <i>Journal of Immunology</i> , <b>2001</b> , 166, 4049-58	5.3	109
216	HSV and glycoprotein J inhibit caspase activation and apoptosis induced by granzyme B or Fas. <i>Journal of Immunology</i> , <b>2001</b> , 167, 3928-35	5.3	101
215	Activation of KaposiN sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus. <i>Journal of Virology</i> , <b>2001</b> , 75, 1378-86	6.6	156
214	Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 32, 214-9	11.6	101
213	Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 33, 763-71	11.6	105
212	Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 184, 1236-45	7	122
211	Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 555-62	7	103
210	Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. <i>Journal of Infectious Diseases</i> , <b>2001</b> , 183, 1466-	<b>7</b> 5	91
209	Letter to the editor: human herpesvirus 6 serologic responses. <i>Journal of Clinical Virology</i> , <b>2001</b> , 21, 103	<b>-1</b> 4.5	О
208	Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. <i>Journal of Clinical Investigation</i> , <b>2001</b> , 107, 505-17	15.9	95
207	Comparison of clinical features, CD4 and CD8 responses among patients with acute HIV-1 infection from Geneva, Seattle and Sydney. <i>Aids</i> , <b>2000</b> , 14, 375-81	3.5	13

# (2000-2000)

200	Herpes simplex type 2 infection in the developing world: is it time to address this disease?. <i>Sexually Transmitted Diseases</i> , <b>2000</b> , 27, 30-1	2.4	8	
20	Modeling plasma virus concentration during primary HIV infection. <i>Journal of Theoretical Biology</i> , <b>2000</b> , 203, 285-301	2.3	358	
<b>2</b> 02	Cervical shedding of herpes simplex virus and cytomegalovirus throughout the menstrual cycle in women infected with human immunodeficiency virus type 1. <i>American Journal of Obstetrics and Gynecology</i> , <b>2000</b> , 183, 948-55	6.4	34	
<b>2</b> 03	Comparison of assays to detect cytomegalovirus shedding in the semen of HIV-infected men.  Journal of Virological Methods, <b>2000</b> , 90, 185-91	2.6	11	
202	High-throughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system. <i>Hepatology</i> , <b>2000</b> , 32, 626-9	11.2	142	
<b>2</b> 01	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , <b>2000</b> , 96, 2055-2061	2.2	422	
200	Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor Ethain repertoire and reduces the level of T-cell oligoclonality. <i>Blood</i> , <b>2000</b> , 95, 1743-17	51 <sup>2.2</sup>	36	
199	Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 182, 950-4	7	34	
198	A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. <i>AIDS Research and Human Retroviruses</i> , <b>2000</b> , 16, 907-19	1.6	55	
197	Mucosal shedding of human herpesvirus 8 in men. <i>New England Journal of Medicine</i> , <b>2000</b> , 343, 1369-7	7 59.2	385	
190	Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 58-63	7	105	
195	Herpes simplex virus type 2 shedding in human immunodeficiency virus-negative men who have sex with men: frequency, patterns, and risk factors. <i>Clinical Infectious Diseases</i> , <b>2000</b> , 30, 261-7	11.6	57	
194	Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 121-31	7	142	
193	Long term persistence of herpes simplex virus-specific CD8+ CTL in persons with frequently recurring genital herpes. <i>Journal of Immunology</i> , <b>2000</b> , 165, 1146-52	5.3	44	
192	Genital herpes and public health: addressing a global problem. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 283, 791-4	27.4	163	
191	Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: the Cardiovascular Health Study.  **Circulation**, 2000**, 102, 2335-40**	16.7	115	
190	Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 181, 354-7	7	114	
189	Antigen-specific T cells localize to the uterine cervix in women with genital herpes simplex virus type 2 infection. <i>Journal of Infectious Diseases</i> , <b>2000</b> , 182, 662-70	7	45	

188	Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. <i>Biology of Blood and Marrow Transplantation</i> , <b>2000</b> , 6, 361-9	4.7	85
187	Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. <i>Lancet, The</i> , <b>2000</b> , 356, 645-9	40	452
186	Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 844-50	59.2	463
185	Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. <i>AIDS Research and Human Retroviruses</i> , <b>2000</b> , 16, 2019	1.6 9-35	143
184	Sensitive method for detection of human herpesviruses 6 and 7 in saliva collected in field studies. Journal of Clinical Microbiology, <b>2000</b> , 38, 1981-3	9.7	57
183	HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 105, 1407-17	15.9	75
182	Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. <i>Blood</i> , <b>2000</b> , 96, 2055-2061	2.2	4
181	Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones <b>2000</b> , 29-44		
180	Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 14-20	8	117
179	Development of a high-throughput quantitative assay for detecting herpes simplex virus DNA in clinical samples. <i>Journal of Clinical Microbiology</i> , <b>1999</b> , 37, 1941-7	9.7	206
178	Successful Modification of a pp65 Antigenemia-Based Early Treatment Strategy for Prevention of Cytomegalovirus Disease in Allogeneic Marrow Transplant Recipients. <i>Blood</i> , <b>1999</b> , 93, 1781-1782	2.2	147
177	Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , <b>1999</b> , 94, 4029-4035	2.2	213
176	Detection of herpes simplex virus DNA in semen of men with genital HSV-2 infection. <i>Sexually Transmitted Diseases</i> , <b>1999</b> , 26, 1-3	2.4	25
175	Human herpesvirus 6 infections after bone marrow transplantation: clinical and virologic manifestations. <i>Journal of Infectious Diseases</i> , <b>1999</b> , 179, 311-8	7	131
174	Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. <i>Journal of Infectious Diseases</i> , <b>1999</b> , 180, 278-84	<b>1</b> 7	103
173	Association of major histocompatibility complex determinants with the development of symptomatic and asymptomatic genital herpes simplex virus type 2 infections. <i>Journal of Infectious Diseases</i> , <b>1999</b> , 179, 1077-85	7	47
172	Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. <i>JAMA - Journal of the American Medical Association</i> , <b>1999</b> , 282, 331-40	27.4	343
171	Reply. Journal of Infectious Diseases, <b>1999</b> , 180, 572-4	7	1

170	HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. <i>AIDS Research and Human Retroviruses</i> , <b>1999</b> , 15, 115-32	1.6	39
169	In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. <i>Nature Medicine</i> , <b>1999</b> , 5, 34-41	50.5	<b>3</b> 00
168	Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. <i>Nature Medicine</i> , <b>1999</b> , 5, 651-5	50.5	365
167	Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro. <i>Journal of Medical Virology</i> , <b>1999</b> , 58, 165-73	19.7	29
166	Cervical shedding of cytomegalovirus in human immunodeficiency virus type 1-infected women. Journal of Medical Virology, <b>1999</b> , 59, 469-473	19.7	27
165	A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 1432-8	59.2	383
164	Outbreak of Stenotrophomonas maltophilia bacteremia among patients undergoing bone marrow transplantation: association with faulty replacement of handwashing soap. <i>Infection Control and Hospital Epidemiology</i> , <b>1999</b> , 20, 756-8	2	32
163	Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. <i>Sexually Transmitted Diseases</i> , <b>1999</b> , 26, 221-5	2.4	38
162	Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. <i>Journal of Clinical Microbiology</i> , <b>1999</b> , 37, 1113-6	9.7	92
161	Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. <i>Journal of Virology</i> , <b>1999</b> , 73, 8950-7	6.6	177
160	An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection. <i>Journal of Virology</i> , <b>1999</b> , 73, 2058-63	6.6	33
159	Successful Modification of a pp65 Antigenemia-Based Early Treatment Strategy for Prevention of Cytomegalovirus Disease in Allogeneic Marrow Transplant Recipients. <i>Blood</i> , <b>1999</b> , 93, 1781-1782	2.2	5
158	Viremia in neonatal herpes simplex virus infections. <i>Pediatric Infectious Disease Journal</i> , <b>1999</b> , 18, 487-9	3.4	81
157	Endemic spread of herpes simplex virus type 1 among adolescent wrestlers and their coaches. <i>Pediatric Infectious Disease Journal</i> , <b>1999</b> , 18, 1108-9	3.4	18
156	Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , <b>1999</b> , 94, 4029-4035	2.2	2
155	Antiretroviral therapy in primary HIV. Advances in Experimental Medicine and Biology, <b>1999</b> , 458, 223-7	3.6	1
154	Reactivities of human sera with human herpesvirus-8-infected BCBL-1 cells and identification of HHV-8-specific proteins and glycoproteins and the encoding cDNAs. <i>Virology</i> , <b>1998</b> , 243, 208-17	3.6	69
153	Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. <i>Nature Medicine</i> , <b>1998</b> , 4, 341-5	50.5	116

152	Tipping the scales of herpes simplex virus reactivation: the important responses are local. <i>Nature Medicine</i> , <b>1998</b> , 4, 381-2	50.5	79
151	Modulation of immunologic responses to HIV-1MN recombinant gp160 vaccine by dose and schedule of administration. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. <i>Vaccine</i> , <b>1998</b> , 16, 493-506	4.1	23
150	Herpes simplex virus-2 infection. An emerging disease?. <i>Infectious Disease Clinics of North America</i> , <b>1998</b> , 12, 47-61	6.5	65
149	Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 320-30	7	265
148	Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 301-9	7	67
147	Herpes simplex virus shedding among human immunodeficiency virus-negative men who have sex with men: site and frequency of shedding. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 178, 978-82	7	30
146	Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 310-9	7	83
145	Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 178, 1616-22	7	197
144	Association between cytomegalovirus seroconversion and upper genital tract infection among women attending a sexually transmitted disease clinic: a prospective study. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 1188-93	7	31
143	Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 1069-72	7	67
142	Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. <i>Journal of Infectious Diseases</i> , <b>1998</b> , 177, 1230-46	7	182
141	Perspectives on switching oral acyclovir from prescription to over-the-counter status: report of a consensus panel. <i>Clinical Infectious Diseases</i> , <b>1998</b> , 26, 659-63	11.6	16
140	Incidence of HIV and sexually transmitted diseases (STD) in a cohort of HIV-negative men who have sex with men (MSM). <i>Aids</i> , <b>1998</b> , 12, 2041-8	3.5	46
139	Raising the consciousness for identifying and controlling viral STDs: fears and frustrationsThomas Parran Award Lecture. <i>Sexually Transmitted Diseases</i> , <b>1998</b> , 25, 58-69	2.4	19
138	Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis. <i>Journal of Virology</i> , <b>1998</b> , 72, 436-41	6.6	85
137	Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. <i>Journal of Virology</i> , <b>1998</b> , 72, 8158-65	6.6	107
136	Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. <i>Journal of Virology</i> , <b>1998</b> , 72, 4288-96	6.6	114
135	Human herpesvirus 8 in the prostate glands of men with KaposiN sarcoma. <i>Journal of Virology</i> , <b>1998</b> , 72, 6223-7	6.6	57

134	Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1998</b> , 17, 303-13		19
133	Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome. <i>Antiviral Therapy</i> , <b>1998</b> , 3, 25-32	1.6	9
132	Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without KaposiN sarcoma. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 176, 775-7	7	45
131	Frequent detection of KaposiN sarcoma-associated herpesvirus (human herpesvirus 8) DNA in saliva of human immunodeficiency virus-infected men: clinical and immunologic correlates. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 176, 94-102	7	191
130	Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 175, 1101-7	7	74
129	A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. <i>Journal of Infectious Diseases</i> , <b>1997</b> , 176, 892-8	7	131
128	Genital herpes in a primary care clinic. Demographic and sexual correlates of herpes simplex type 2 infections. <i>Sexually Transmitted Diseases</i> , <b>1997</b> , 24, 149-55	2.4	66
127	The acquisition of herpes simplex virus during pregnancy. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 509-15	59.2	595
126	Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. <i>New England Journal of Medicine</i> , <b>1997</b> , 337, 1267-74	59.2	482
125	Cesarean delivery in women with genital herpes in washington state, 1989-1991. <i>Infectious Diseases in Obstetrics and Gynecology</i> , <b>1997</b> , 5, 29-35	2.4	
124	Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. <i>American Journal of Obstetrics and Gynecology</i> , <b>1997</b> , 177, 450-4	6.4	35
123	Herpes simplex virus type 2 detection by culture and polymerase chain reaction and relationship to genital symptoms and cervical antibody status during the third trimester of pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , <b>1997</b> , 176, 443-51	6.4	33
122	A randomized, double-blind trial of parenteral low dose versus high dose interferon-beta in combination with cryotherapy for treatment of condyloma acuminatum. <i>Antiviral Research</i> , <b>1997</b> , 35, 41-52	10.8	12
121	Serial in vivo passage of HIV-1 infection in Macaca nemestrina. <i>Virology</i> , <b>1997</b> , 238, 336-43	3.6	26
120	Cesarean delivery in women with genital herpes in Washington state, 1989¶991. <i>Infectious Diseases in Obstetrics and Gynecology</i> , <b>1997</b> , 5, 29-35	2.4	3
119	Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 1011-7	59.2	616
118	Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. <i>Journal of Infectious Diseases</i> , <b>1996</b> , 174, 1162-7	7	184
117	Therapy for human immunodeficiency virus infection what have we learned?. <i>New England Journal of Medicine</i> , <b>1996</b> , 335, 1142-4	59.2	30

116	Asymptomatic maternal shedding of herpes simplex virus at the onset of labor: relationship to preterm labor. <i>Obstetrics and Gynecology</i> , <b>1996</b> , 87, 483-8	4.9	51
115	Cervical antibodies to herpes simplex virus proteins in pregnancy and puerperium: a pilot study. <i>Infectious Diseases in Obstetrics and Gynecology</i> , <b>1996</b> , 4, 7-15	2.4	2
114	Lack of detection of HSV DNA in PBMCs and lymph nodes of HIV-infected persons. <i>Journal of Medical Virology</i> , <b>1996</b> , 48, 47	19.7	1
113	T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. <i>Nature Medicine</i> , <b>1996</b> , 2, 216-23	50.5	517
112	Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. <i>AIDS Research and Human Retroviruses</i> , <b>1996</b> , 12, 683-93	1.6	70
111	Cervical antibodies to herpes simplex virus proteins in pregnancy and puerperium: A pilot study. <i>Infectious Diseases in Obstetrics and Gynecology</i> , <b>1996</b> , 4, 7-15	2.4	
110	Subclinical shedding of HSV: its potential for reduction by antiviral therapy. <i>Advances in Experimental Medicine and Biology</i> , <b>1996</b> , 394, 11-6	3.6	7
109	Recurrence Rates of Genital Herpes. <i>Annals of Internal Medicine</i> , <b>1995</b> , 122, 883	8	
108	Virologic characteristics of subclinical and symptomatic genital herpes infections. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 770-5	59.2	427
107	Herpesvirus infections in persons infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , <b>1995</b> , 21 Suppl 1, S114-20	11.6	80
106	Frequency and reactivation of nongenital lesions among patients with genital herpes simplex virus. <i>American Journal of Medicine</i> , <b>1995</b> , 98, 237-42	2.4	31
105	A comparison between detailed and simple histories in the diagnosis of genital herpes complicating pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , <b>1995</b> , 172, 1299-303	6.4	37
104	Intermittent Shedding of Human Immunodeficiency Virus in Semen: Implications for Sexual Transmission. <i>Journal of Urology</i> , <b>1995</b> , 154, 1035-1040	2.5	59
103	Safety, pharmacokinetics, and antiviral response of CD4-immunoglobulin G by intravenous bolus in AIDS and AIDS-related complex. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1995</b> , 10, 150-6		4
102	Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology, <b>1995</b> , 22, 1-9	11.2	134
101	Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. <i>Journal of Infectious Diseases</i> , <b>1994</b> , 169, 41-7	7	40
100	Analysis of cytotoxic T lymphocyte responses to SIV proteins in SIV-infected macaques using antigen-specific stimulation with recombinant vaccinia and fowl poxviruses. <i>AIDS Research and Human Retroviruses</i> , <b>1994</b> , 10, 551-60	1.6	15
99	Direct recovery of herpes simplex virus (HSV)-specific T lymphocyte clones from recurrent genital HSV-2 lesions. <i>Journal of Infectious Diseases</i> , <b>1994</b> , 169, 956-61	7	126

98	Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network. <i>AIDS Research and Human Retroviruses</i> , <b>1994</b> , 10, 1713-23	1.6	53
97	HIV-infected macrophages as efficient stimulator cells for detection of cytotoxic T cell responses to HIV in seronegative and seropositive vaccine recipients. <i>AIDS Research and Human Retroviruses</i> , <b>1994</b> , 10, 541-9	1.6	9
96	Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. BMJ: British Medical Journal, <b>1994</b> , 309, 1325-9		174
95	Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>1993</b> , 328, 465-70	59.2	741
94	Dual infection with human papillomavirus in a population with overt genital condylomas. <i>Journal of the American Academy of Dermatology</i> , <b>1993</b> , 28, 434-42	4.5	18
93	The natural history of HIV infection: implications for the assessment of antiretroviral therapy. <i>Clinical Infectious Diseases</i> , <b>1993</b> , 16 Suppl 1, S2-6	11.6	8
92	Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. <i>Journal of Infectious Diseases</i> , <b>1993</b> , 168, 1387-95	7	77
91	Underestimation of HSV-2 seroprevalence in a high-risk population by microneutralization assay. <i>Sexually Transmitted Diseases</i> , <b>1993</b> , 20, 230-5	2.4	18
90	Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. <i>New England Journal of Medicine</i> , <b>1993</b> , 329, 156-61	59.2	265
89	Penile intraepithelial neoplasia: clinical presentation and an analysis of the physical state of human papillomavirus DNA. <i>Journal of Infectious Diseases</i> , <b>1993</b> , 168, 38-46	7	23
88	Clinical perspectives in the treatment of HIV disease: the role of didanosine. Introduction. <i>Clinical Infectious Diseases</i> , <b>1993</b> , 16 Suppl 1, S1	11.6	
87	Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. <i>Virology</i> , <b>1993</b> , 195, 422-31	3.6	39
86	Treatment of HIV infectionprogress in perspective. New England Journal of Medicine, 1992, 326, 484-6	59.2	16
85	Underdiagnosis of genital herpes by current clinical and viral-isolation procedures. <i>New England Journal of Medicine</i> , <b>1992</b> , 326, 1533-9	59.2	241
84	Evaluation of new anti-infective drugs for the treatment of chancroid. Infectious Diseases Society of America and the Food and Drug Administration. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 15 Suppl 1, S108-14	11.6	5
83	Evaluation of new anti-infective drugs for the treatment of vaginal infections. Infectious Diseases Society of America and the Food and Drug Administration. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 15 Suppl 1, S115-22	11.6	9
82	Evaluation of new anti-infective drugs for the treatment of syphilis. Infectious Diseases Society of America and the Food and Drug Administration. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 15 Suppl 1, S140-7	11.6	7
81	Evaluation of new anti-infective drugs for the treatment of sexually transmitted chlamydial infections and related clinical syndromes. Infectious Diseases Society of America and the Food and Drug Administration. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 15 Suppl 1, S131-9	11.6	5

80	Evaluation of new anti-infective drugs for the treatment of uncomplicated gonorrhea in adults and adolescents. Infectious Diseases Society of America and the Food and Drug Administration. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 15 Suppl 1, S123-30	11.6	19
79	Special issues in clinical trials of new anti-infective drugs for the treatment of sexually transmitted diseases. Infectious Diseases Society of America and the Food and Drug Administration. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 15 Suppl 1, S96-8	11.6	1
78	Evaluation of new anti-infective drugs for the treatment of genital infections due to herpes simplex virus. Infectious Diseases Society of America and the Food and Drug Administration. <i>Clinical Infectious Diseases</i> , <b>1992</b> , 15 Suppl 1, S99-107	11.6	5
77	A randomized, double-blind, phase I/II trial of tumor necrosis factor and interferon-gamma for treatment of AIDS-related complex (Protocol 025 from the AIDS Clinical Trials Group). <i>AIDS Research and Human Retroviruses</i> , <b>1992</b> , 8, 581-7	1.6	18
76	Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. <i>American Journal of Epidemiology</i> , <b>1992</b> , 135, 1093-102	3.8	132
75	Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine,	4.8	83
74	Clinical studies with herpes simplex virus type 2 Curtis strain vaccine. <i>Clinical Infectious Diseases</i> , <b>1991</b> , 13 Suppl 11, S904-5	11.6	3
73	Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 450-4	59.2	337
72	Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 1247-52	59.2	387
71	A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 444-9	59.2	318
70	A reduced dose of zidovudine in patients with AIDS. New England Journal of Medicine, 1991, 324, 994-6	59.2	1
69	Pharmacokinetics of acyclovir in the term human pregnancy and neonate. <i>American Journal of Obstetrics and Gynecology</i> , <b>1991</b> , 164, 569-76	6.4	124
68	The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. <i>Sexually Transmitted Diseases</i> , <b>1990</b> , 17, 90-4	2.4	116
67	Sexually transmitted diseases in victims of rape. New England Journal of Medicine, 1990, 322, 713-6	59.2	156
66	A pilot study of low-dose zidovudine in human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1990</b> , 323, 1015-21	59.2	184
65	Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 941-9	59.2	1113
64	Double-blind randomized clinical trial of self-administered podofilox solution versus vehicle in the treatment of genital warts. <i>American Journal of Medicine</i> , <b>1990</b> , 88, 465-9	2.4	73
63	A selective defect in tissue factor mRNA expression in monocytes from AIDS patients. <i>Clinical Immunology and Immunopathology</i> , <b>1990</b> , 54, 1-13		7

62 Electron Microscopic observation on the semen of HIV-positive men. *Proceedings Annual Meeting Electron Microscopy Society of America*, **1990**, 48, 348-349

61	Plasma viremia in human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , <b>1989</b> , 321, 1626-31	59.2	534
60	Isolation of human immunodeficiency virus from genital ulcers in Nairobi prostitutes. <i>Journal of Infectious Diseases</i> , <b>1989</b> , 160, 380-4	7	199
59	Differential effect of systemic acyclovir treatment of genital HSV-2 infections on antibody responses to individual HSV-2 proteins. <i>Journal of Medical Virology</i> , <b>1988</b> , 24, 309-19	19.7	19
58	Analysis of a major target of the human immune response to cytomegalovirus using monoclonal antibodies. <i>Journal of Medical Virology</i> , <b>1988</b> , 25, 237-43	19.7	5
57	Tolerance and efficacy of recombinant human interferon gamma in the treatment of refractory genital warts. <i>American Journal of Medicine</i> , <b>1988</b> , 85, 183-8	2.4	43
56	Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome. <i>Lancet, The</i> , <b>1988</b> , 1, 1-4	40	154
55	First-episode, recurrent, and asymptomatic herpes simplex infections. <i>Journal of the American Academy of Dermatology</i> , <b>1988</b> , 18, 169-72	4.5	37
54	Transmission of genital herpes in couples with one symptomatic and one asymptomatic partner: a prospective study. <i>Journal of Infectious Diseases</i> , <b>1988</b> , 157, 1169-77	7	121
53	Genital ulceration as a risk factor for human immunodeficiency virus infection. <i>Aids</i> , <b>1988</b> , 2, 47-50	3.5	270
52	Nosocomial transmission of rotavirus infection. <i>Pediatric Infectious Disease Journal</i> , <b>1988</b> , 7, 103-9	3.4	51
51	Effects on infants of a first episode of genital herpes during pregnancy. <i>New England Journal of Medicine</i> , <b>1987</b> , 317, 1246-51	59.2	231
50	Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type. <i>New England Journal of Medicine</i> , <b>1987</b> , 316, 1444-9	59.2	347
49	Neonatal herpes simplex virus infection. <i>Pediatric Infectious Disease Journal</i> , <b>1987</b> , 6, 1057-1061	3.4	8
48	Cytomegalovirus infection in homosexual men. Relationship to sexual practices, antibody to human immunodeficiency virus, and cell-mediated immunity. <i>American Journal of Medicine</i> , <b>1987</b> , 82, 593-601	2.4	88
47	Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. <i>New England Journal of Medicine</i> , <b>1987</b> , 317, 973-7	59.2	559
46	Treatment of Herpes Simplex Virus Infections. <i>Clinics in Laboratory Medicine</i> , <b>1987</b> , 7, 815-829	2.1	3
45	Presentation of neonatal herpes simplex virus infections: implications for a change in therapeutic strategy. <i>Pediatric Infectious Disease Journal</i> , <b>1986</b> , 5, 309-14	3.4	57

44	Infections with herpes simplex viruses (1). New England Journal of Medicine, 1986, 314, 686-91	59.2	487
43	Infections with herpes simplex viruses (2). New England Journal of Medicine, 1986, 314, 749-57	59.2	460
42	Laboratory diagnosis of herpes simplex virus infections. Principles guiding the development of rapid diagnostic tests. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>1986</b> , 4, 111S-119S	2.9	44
41	Etiology of cervical inflammation. American Journal of Obstetrics and Gynecology, 1986, 154, 556-64	6.4	80
40	Spectrum of rectal biopsy abnormalities in homosexual men with intestinal symptoms. <i>Gastroenterology</i> , <b>1986</b> , 91, 651-9	13.3	42
39	Frequency of acquisition of first-episode genital infection with herpes simplex virus from symptomatic and asymptomatic source contacts. <i>Sexually Transmitted Diseases</i> , <b>1985</b> , 12, 33-9	2.4	183
38	Humoral immune response to HSV-1 and HSV-2 viral proteins in patients with primary genital herpes. <i>Journal of Medical Virology</i> , <b>1985</b> , 17, 153-66	19.7	72
37	Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. <i>Sexually Transmitted Diseases</i> , <b>1985</b> , 12, 215-8	2.4	32
36	Adenovirus infections in patients undergoing bone-marrow transplantation. <i>New England Journal of Medicine</i> , <b>1985</b> , 312, 529-33	59.2	375
35	Cell-mediated immunity in human herpesvirus infection: analysis by monoclonal antibodies. <i>Clinical Immunology and Immunopathology</i> , <b>1985</b> , 37, 83-92		2
34	Genital herpes in pregnancy: risk factors associated with recurrences and asymptomatic viral shedding. <i>American Journal of Obstetrics and Gynecology</i> , <b>1985</b> , 153, 24-30	6.4	74
33	The Natural History of Genital Herpes Simplex Virus <b>1985</b> , 1-35		2
32	A collaborative study of patient-initiated treatment of recurrent genital herpes with topical acyclovir or placebo. <i>Journal of Infectious Diseases</i> , <b>1984</b> , 150, 1-6	7	62
31	Prevalence and incidence of herpesvirus infections among homosexually active men. <i>Journal of Infectious Diseases</i> , <b>1984</b> , 149, 1026-7	7	45
30	Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. Journal of Infectious Diseases, <b>1984</b> , 149, 645-6	7	54
29	A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. <i>New England Journal of Medicine</i> , <b>1984</b> , 310, 1551-6	59.2	324
28	Herpes simplex viral pneumonitis in childhood. <i>Journal of Pediatrics</i> , <b>1984</b> , 104, 211-5	3.6	25
27	Genital Herpes Simplex Virus Infections in Adults. <i>Urologic Clinics of North America</i> , <b>1984</b> , 11, 103-119	2.9	8

26	Transmission of herpes simplex virus from father to neonate. <i>Journal of Pediatrics</i> , <b>1983</b> , 103, 905-7	3.6	38
25	Acquisition of neonatal HSV-1 infection from a paternal source contact. <i>Journal of Pediatrics</i> , <b>1983</b> , 103, 908-10	3.6	48
24	The polymicrobial origin of intestinal infections in homosexual men. <i>New England Journal of Medicine</i> , <b>1983</b> , 309, 576-82	59.2	247
23	Herpes simplex virus proctitis in homosexual men. Clinical, sigmoidoscopic, and histopathological features. <i>New England Journal of Medicine</i> , <b>1983</b> , 308, 868-71	59.2	227
22	Genital herpes simplex virus infections: clinical manifestations, course, and complications. <i>Annals of Internal Medicine</i> , <b>1983</b> , 98, 958-72	8	632
21	Intravenous acyclovir for the treatment of primary genital herpes. <i>Annals of Internal Medicine</i> , <b>1983</b> , 98, 914-21	8	134
20	Historical findings in subjects from a high socioeconomic group who have genital infections with herpes simplex virus. <i>Sexually Transmitted Diseases</i> , <b>1982</b> , 9, 15-20	2.4	18
19	Recurrent genital herpes simplex virus infection in pregnancy: infant outcome and frequency of asymptomatic recurrences. <i>American Journal of Obstetrics and Gynecology</i> , <b>1982</b> , 143, 75-84	6.4	100
18	Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections. <i>American Journal of Medicine</i> , <b>1982</b> , 73, 326-34	2.4	80
17	Patient-initiated therapy for recurrent genital herpetic infections. <i>American Journal of Medicine</i> , <b>1982</b> , 73, 342-6	2.4	8
16	A trial of topical acyclovir in genital herpes simplex virus infections. <i>New England Journal of Medicine</i> , <b>1982</b> , 306, 1313-9	59.2	276
15	The etiology of anorectal infections in homosexual men. <i>American Journal of Medicine</i> , <b>1981</b> , 71, 395-4	062.4	103
14	Risk of recurrence after first episodes of genital herpes. Relation to HSV type and antibody response. <i>New England Journal of Medicine</i> , <b>1981</b> , 305, 315-9	59.2	299
13	Atypical generalized zoster with lymphadenitis mimicking lymphoma. <i>New England Journal of Medicine</i> , <b>1980</b> , 302, 848-51	59.2	19
12	Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. <i>New England Journal of Medicine</i> , <b>1980</b> , 302, 435-8	59.2	183
11	Ineffectiveness of topical ether for the treatment of genital herpes simplex virus infection. <i>New England Journal of Medicine</i> , <b>1978</b> , 299, 237-9	59.2	46
10	Cellular immune response in genital herpes simplex virus infection. <i>New England Journal of Medicine</i> , <b>1978</b> , 299, 986-91	59.2	86
9	A nationwide outbreak of Reye <b>N</b> Syndrome. Its epidemiologic relationship of influenza B. <i>American Journal of Medicine</i> , <b>1976</b> , 61, 615-25	2.4	132

8	Serum neutralizing antibody after rabies postexposure prophylaxis. <i>Annals of Internal Medicine</i> , <b>1976</b> , 85, 170-6	8	11
7	HBs-Ag-negative hepatitis in a hemodialysis unit: relation to Epstein-Barr virus. <i>New England Journal of Medicine</i> , <b>1975</b> , 293, 1273-8	59.2	36
6	HSV: persistence in the population: epidemiology, transmission656-672		35
5	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico		5
4	Elimination of HSV-2 infected cells is mediated predominantly by paracrine effects of tissue-resident T cell derived cytokines		1
3	Evaluating the Efficacy of COVID-19 Vaccines		1
2	Vaccines that prevent SARS-CoV-2 transmission may prevent or dampen a spring wave of COVID-19 cases and deaths in 2021		4
1	Increased oral Epstein-Barr virus shedding with HIV-1 co-infection is due to a combination of B cell activation and impaired cellular immune control		2